© 2021 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
Retinal specialists have a new therapy in their armoury: on January 24th 2007, the European Commission approved ranibizumab (Lucentis, Novartis) for the treatment of patients with wet age-related macular degeneration (AMD).
Related Content: